EC Pharmacology and Toxicology

Introduction: The HIV-AIDS pandemic remains a scientific and political challenge worldwide. Antiretroviral treatment has decreased the development of AIDS among those who are HIV+. However, psychosocial barriers may impair proper treatment for HIV+ patients. Psychosocial barriers are related to treatment, patient, health system access and health team characteristics.

Objective: Establish the relationship between the medication storage and psychosocial barriers in HIV positive patients with virological failure in a health provider institution in the Colombian Orinoquia and Amazonia.

Materials and Methods: Cross-sectional study with descriptive analysis was carried out for the relationship between the preservation of medications: chi-square or Fisher. Subjects were patients treated in a health care institution.

Results: Virological failure prevalence is 31.6%: 47.95% poor medication storage, 20.55% do not have electricity, 49.32% did not use or did not have a refrigerator. A relationship of all psychosocial barriers was found to be related to poor medication storage; significant: "exhaustion, having to take the medication very often" 89.47%; "barriers to transportation to the healthcare institution" 42.11%. For those who conserved medication, the median hours of energy was: 4 hours (p = 0.000).

Conclusion: A relationship was found between medications storage and available hours of electrical power, psychosocial barriers are related to poor medication storage in these patients with virological failure. It is important to explore the prevalence of virological failure and characteristics related to these barriers, nationally and internationally.

Keywords: Virological Failure; HIV-AIDS Pandemic; HIV+ Patients

1. Fauci AS DR. “Pathogenesis of HIV and SIV”. Retroviruses (1997).
2. German Advisory Committee Blood SAoPTbB. “Human Immunodeficiency Virus (HIV)”. Transfusion Medicine and Hemotherapy 3 (2016): 203-222.
3. Carstens AKELMJAEB. Virus Taxonomy (2011).
4. Briggs JA., et al. “Structural organization of authentic, mature HIV-1 virions and cores”. The EMBO Journal7 (2003): 1707-1715.
5. Munro JB and Mothes W. “Structure and Dynamics of the Native HIV-1 Env Trimer”. Journal of Virology 11 (2015): 5752-5755.
6. Reitz MS and Gallo RC. “171 - Human Immunodeficiency Viruses”. In: Bennett JE, Dolin R, Blaser MJ, editors. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases (Eighth Edition). Philadelphia: W.B. Saunders (2015): 2054-2065.
7. Goodsell D. “HIV Capsid”. PDB 101 (2013).
8. Le Rouzic E and Benichou S. “The Vpr protein from HIV-1: distinct roles along the viral life cycle”. Retrovirology 2 (2005): 11.
9. Group TWB. “Prevalence of HIV, total (%) of population ages” (2021): 15-49.
10. Robbins GK., et al. “Predicting virologic failure in an HIV clinic”. Clinical Infectious Diseases 5 (2010): 779-786.
11. Ayele G., et al. “Prevalence and associated factors of treatment failure among HIV/AIDS patients on HAART attending University of Gondar Referral Hospital Northwest Ethiopia”. BMC Immunology 1 (2018): 37.
12. Abebaw A., et al. Research Square (2020).
13. Sarmiento Cadglecáagpafflmfca. Guía Para El Manejo De Vih/Sida Basada En La Evidencia Colombia (2017).
14. De La Hoz JM., et al. “Characterization of treatment failure in HIV positive patients in the Colombian Caribbean region”. Colombia Médica 45 (2014): 162-167.